Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, 775 20, Czech Republic.
First Department of Medicine - Cardioangiology, St. Anne's Faculty Hospital Brno, Brno, Czech Republic.
ESC Heart Fail. 2021 Oct;8(5):3800-3808. doi: 10.1002/ehf2.13559. Epub 2021 Aug 19.
A retrospective nationwide observational analysis of diagnoses, procedures, and treatment reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018.
Prevalence of heart failure (HF) patients increased from 176 496 (1679.4 per 100 000 population) in 2012 to 285 745 (2689.0 per 100 000 population) patients in 2018 (mean age 74.4 ± 12.8 years). In the last years, a stable incidence of HF patients was observed (544 per 100 000 population in 2016 vs. 551 per 100 000 population in 2018; P = 0.310). Mortality rate decreased from 20.55% in 2012 to 15.89% in 2018. The number of hospitalized patients remained similar (318.2 per 100 000 population in 2012 vs. 311.8 per 100 000 population in 2018; P = 0.479). The most used drugs were diuretics (173 295; 60.6%) and beta-blockers (178 823; 62.6%), followed by angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (angiotensin-converting enzyme inhibitors 120.581; 42.2%; angiotensin II receptor blockers 47 216; 16.5%). Even though the whole number of implanted devices in HF patients increased steadily (from 25 205 in 2012 to 45 363 in 2018), the prevalence of all devices (pacemakers and defibrillators) in the HF patients remained about the same (14.3% in 2012; 15.9% in 2018).
The study included all patients with HF in the Czech Republic. These are the first nationwide data of HF epidemiology in the Eastern bloc. The incidence of HF remains stable in the last years. Due to aging of the population, the prevalence of HF significantly increased in the last 6 years. Despite a continuous increase in the prevalence of HF and a suboptimal utilization of its pharmacological therapy, mortality decreased, and the number of hospitalized patients remained the same.
对捷克共和国国家报销健康服务登记处 2012 年至 2018 年报告的诊断、程序和治疗进行回顾性全国性观察分析。
心力衰竭（HF）患者的患病率从 2012 年的 176496 例（每 10 万人中有 1679.4 例）增加到 2018 年的 285745 例（每 10 万人中有 2689.0 例）（平均年龄 74.4±12.8 岁）。近年来，HF 患者的发病率保持稳定（2016 年每 10 万人中有 544 例，2018 年每 10 万人中有 551 例；P=0.310）。死亡率从 2012 年的 20.55%下降到 2018 年的 15.89%。住院患者人数保持不变（2012 年每 10 万人中有 318.2 例，2018 年每 10 万人中有 311.8 例；P=0.479）。使用最多的药物是利尿剂（173295 例；60.6%）和β受体阻滞剂（178823 例；62.6%），其次是血管紧张素转换酶抑制剂/血管紧张素 II 受体阻滞剂（血管紧张素转换酶抑制剂 120581 例；42.2%；血管紧张素 II 受体阻滞剂 47216 例；16.5%）。尽管心力衰竭患者植入设备的总数稳步增加（从 2012 年的 25205 例增加到 2018 年的 45363 例），但心力衰竭患者所有设备（起搏器和除颤器）的患病率基本保持不变（2012 年为 14.3%；2018 年为 15.9%）。
该研究纳入了捷克共和国所有心力衰竭患者。这是东欧心力衰竭流行病学的首次全国性数据。近年来，心力衰竭的发病率保持稳定。由于人口老龄化，心力衰竭的患病率在过去 6 年显著增加。尽管心力衰竭的患病率不断增加，且其药物治疗的效果不理想，但死亡率下降，住院患者人数保持不变。
